ARMS-I (a Formulation of Cetylpyridinium Chloride -CPC)
Status:
Withdrawn
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
This is a single center study to evaluate the pharmacokinetics of ARMS-I a formulation that
incorporates cetylpyridinium chloride (CPC), administered once as a single dose of three
sprays orally, followed by multiple dosing (3x daily oral sprays) over days 3-6 and then a
repeat pharmacokinetic study during the final oral dose administered as the first dose on day
7 to ascertain CPC accumulation.
Phase:
Phase 2
Details
Lead Sponsor:
University of Toledo Health Science Campus
Collaborators:
ARMS Pharmaceutical LLC Pediatric Pharmacology Research Center ProMedica Health System The University of Toledo